Pulmonary Delivery of Hydroxychloroquine Nanostructured Lipid Carrier as a Potential Treatment of COVID-19

Coronavirus Disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2. Pneumonia is considered the most severe and long-term complication of COVID-19. Among other drugs, hydroxychloroquine (HCQ) was repurposed for the management of COVID-19; however, low efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Ahmed Shaker, Alrashedi, Mohsen Geza, Ahmed, Osama Abdelhakim Aly, Ibrahim, Ibrahim M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269041/
https://www.ncbi.nlm.nih.gov/pubmed/35808662
http://dx.doi.org/10.3390/polym14132616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269041/
https://www.ncbi.nlm.nih.gov/pubmed/35808662
http://dx.doi.org/10.3390/polym14132616

Ejemplares similares